Setting new standards in information exchange for the pharmaceutical and biotech industry
Drug Delivery Highlights in 2017
September 13, 2018
Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche, delivers a “Year in Review” presentation to kick off the annual Partnerships in Drug Delivery (PODD) conference. During the presentation, Lueckel discusses some of the year’s biggest innovations in the drug delivery market and provides a glimpse into the sector’s future.
At PODD 2017, Lueckel highlighted a variety of drug delivery innovations in her Year in Review, such as:
- Small Molecules
Small molecule drugs administered via immediate-release tablets or capsules are becoming exceedingly important for healthcare providers and their patients. Meanwhile, 2017 proved to be a landmark year for small molecule drugs, as several advancements were announced across the small molecule drug delivery market.
Pfizer in August announced the U.S. Food and Drug Administration (FDA) approved Besponsa, a CD22-directed antibody-drug conjugate for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Additionally, the FDA approved Aliqopa, a kinase inhibitor that blocks several enzymes that promote cell growth and may be used to treat adults with relapsed follicular lymphoma.
Therapeutic peptides are available to treat rheumatoid arthritis, cancer and other medical issues. Last year, the FDA approved Trulance, a peptide-based treatment that stimulates the secretion of intestinal fluid and supports regular bowel function.
The global peptide therapeutics market is projected to be worth more than $48 billion by 2025, according to industry analyst Grand View Research. As healthcare providers search for innovative ways to address patients’ medical problems, the demand for therapeutic peptides may increase in the years to come.
- Antibodies and Proteins
2017 was “the year of subcutaneous administration” of antibodies and proteins, Lueckel said. Two key innovations highlighted the growing interest in antibodies and proteins for drug delivery: C1 esterase inhibitor and Benlysta treatments.
The C1 esterase inhibitor treatment can be used to address systemic lupus erythematosus, and it can be administered by a patient on his or her own. Comparatively, Benlysta offers an FDA-approved prescription infusion or self-injectable medication to treat lupus symptoms.
- Connected Health
Technology constantly evolves. As such, healthcare providers are integrating technology into their drug delivery methods like never before.
Several smart devices illustrate the link between connected health and drug delivery. For instance, a patch was developed last year that a patient can wear on his or her stomach; the patch includes a smart sensor that indicates if a patient has taken his or her daily medications. Furthermore, smart touch monitoring for the Symbicort inhalation aerosol is being evaluated as a potential way to enhance patient medication adherence.
Ultimately, innovation is most impactful when it benefits the patient, Lueckel indicated. Healthcare providers remain on the lookout for innovation opportunities, and as a result, the future looks bright for the global drug delivery market.
For those who want to learn more about the current state of the global drug delivery market, Lueckel will launch this year’s PODD event with a Year in Review. Read about to Lueckel’s 2016 Year in Review here or listen to it here. To find out more about PODD 2018, click here to view the conference agenda.